hrp0084p1-105 | Perinatal | ESPE2015

Fluoxetine Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapy

Giri Dinesh , Yung Zoe , Stirrup Kelly , Didi Mo , Seniappan Senthil

Background: Lanreotide is a long acting somatostatin analogue that has been used successfully in the treatment of congenital hyperinsulinism (CHI) in patients who are unresponsive or intolerant to diazoxide. Antidepressant drugs are reported to cause alterations in blood glucose homeostasis in adults with diabetes mellitus. We report a patient with persistent CHI on Lanreotide therapy, who developed recurrent hypoglycaemia following Fluoxetine therapy.Ca...

hrp0084p2-495 | Hypo | ESPE2015

Rapid Biochemical Evaluation Aids Timely Management of Congenital Hyperinsulinism

Swain Georgia , Park Julie , Stirrup Kelly , Yung Zoe , Senniappan Senthil , Didi Mohammed

Background: Congenital Hyperinsulinism (CHI) is the commonest cause of persistent neonatal hypoglycaemia and is characterised by inappropriately detectable plasma insulin during hypoglycaemia. Management depends on the timely analysis of biochemical parameters, which would help initiate appropriate management and avoid potential neurological compromise. The technical difficulties in sending the appropriate sample and the delay in processing the sample in the lab sometimes cont...

hrp0094p2-233 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) | ESPE2021

Diazoxide Responsive Congenital Hyperinsulinism

Lohiya Nikhil , Cassidy Kelly , Yung Zoe , Erlandson-Parry Karen , Wright Samantha , Gait Lucy , Didi Mohammed , Senniappan Senthil ,

Introduction: Congenital Hyperinsulism (CHI) is a common cause of recurrent and persistent hypoglycemia in the neonatal period. Diazoxide is the first line medication used for the management of CHI. We report the clinical profile and the management outcome of a large cohort of patients with diazoxide responsive CHI.Methodology: A retrospective data collection including antenatal, perinatal and postnatal clinical parameters, laboratory di...

hrp0086rfc1.7 | Adrenals | ESPE2016

The Recovery of Adrenal Function in Children with Chronic Asthma Assessed by Low Dose Short Synacthen Test (LDSST)

Gangadharan Arundoss , McCoy Paul , McGuigan Michael , Didi Mohammed , Das Urmi , Dharmaraj Poonam , Senniappan Senthil , Ramakrishnan Renuka , Yung Zoe , Hatchard Lynn , Blundell Pauline , Stirrup Kelly , Blair Joanne

Background: Hypothalamic-Pituitary–Adrenal (HPA) axis suppression is common during inhaled corticosteroid (ICS) treatment of asthma, and deaths due to adrenal crisis are described. Little is known about the optimal treatment or recovery of ICS induced HPA axis suppression.Aims: To describe the treatment and outcomes of children with ICS induced HPA suppression diagnosed on the low dose short Synacthen test (LDSST).Method: The ...

hrp0095p1-354 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Single centre experience of using 6 monthly GnRH analogues in the paediatric population

Apperley Louise , Dharmaraj Poonam , Blair Joanne , Ramakrishnan Renuka , Das Urmi , Didi Mohammed , Laing Peter , Yung Zoe , Cassidy Kelly , Blundell Pauline , Jarvis Charlotte , Parkinson Jennifer , Senniappan Senthil

Background: Mounting evidence points to an association between increased glucocorticoid (GC) action and weight gain. However, the response to GCs is not only determined by GC serum concentrations, but also by individual differences in tissue-specific sensitivity, influenced by genetic and acquired (e.g. disease-related) factors. The extent to which differences in GC sensitivity may influence development of (abdominal) obesity, or vice versa, is poorly understo...